Lupin Announces FDA Approval of SOLOSEC (Secnidazole)
Summary : SOLOSEC® demonstrated a 92.2% clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3…
Summary : SOLOSEC® demonstrated a 92.2% clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3…
KEYPOINTS: The product is a generic version of the Lupin Atlantis Holdings, S A Corporation’s Antara capsules Fenofibrate Capsules (RLD: Antara Capsules)…
Keypoints Dr. Reddy’s Laboratories said it has received approval from the US health regulator to market Lenalidomide capsules, used to treat multiple…